BIO89-100
Phase 3Small molecule
89bioBIO89-100 is one of 6 small molecule programs targeting NASH/MASH. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in NASH/MASH
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskApproved
Farxiga
AstraZenecaApproved
Rezdiffra
Madrigal PharmaceuticalsApproved
Ocaliva
IIntercept Pharmaceuticals
Approved
Mounjaro
Eli LillyPhase 2
BIO89-100
89bioPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BIO89-100. EMBL-EBI & Wellcome Sanger Institute.
- [4]